Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for apathy and impulsivity in progressive supranuclear palsy
ISRCTN99462035Phase 2Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Apr 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of atomoxetine in progressive supranuclear palsy (PSP) (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoints: Cambridge Behavioural Inventory Revised Apathy-Impulsivity Composite Score, Deaths and discontinuations due to adverse events and 1 more. Started Apr 2021; status: completed.
02
Drugs
atomoxetine
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on ISRCTN99462035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN99462035.